Ameriprise’s Rocket Pharmaceuticals RCKT Stock Holding History

Ameriprise’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$941K	Buy	275,009 +262,011	+2,016%	+$871K	﹤0.01%	3431
2026 Q1	$46.5K	Sell	12,998 -62	-0.5%	-$246	﹤0.01%	4004
2025 Q4	$45.8K	Sell	13,060 -140	-1%	-$479	﹤0.01%	4043
2025 Q3	$43K	Buy	+13,200	New	+$41.6K	﹤0.01%	4023
2025 Q2	–	Sell	-12,384	Closed	-$82.6K	–	4100
2025 Q1	$82.6K	Buy	+12,384	New	+$122K	﹤0.01%	3902
2022 Q3	–	Sell	-82,720	Closed	-$1.14M	–	4019
2022 Q2	$1.14M	Buy	82,720 +2,855	+4%	+$34K	﹤0.01%	3066
2022 Q1	$1.27M	Sell	79,865 -40	-0.1%	-$691	﹤0.01%	3109
2021 Q4	$1.74M	Buy	79,905 +8,550	+12%	+$233K	﹤0.01%	3009
2021 Q3	$2.13M	Sell	71,355 -2,775	-4%	-$101K	﹤0.01%	2846
2021 Q2	$3.28M	Buy	74,130 +24,568	+50%	+$1.07M	﹤0.01%	2702
2021 Q1	$2.2M	Sell	49,562 -3,679	-7%	-$202K	﹤0.01%	2823
2020 Q4	$2.92M	Buy	+53,241	New	+$1.94M	﹤0.01%	2605

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ameriprise's RCKT Position: Q2 2026 in Review

Ameriprise increased its Rocket Pharmaceuticals (RCKT) stake by 2,016% in Q2 2026, buying an estimated $871K and bringing the position to 275,009 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #3431.

Ameriprise first reported a position in RCKT in Q4 2020 and has held it in 12 quarters since. The position peaked at $3.28M in Q2 2021. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

Ameriprise held 275,009 shares of Rocket Pharmaceuticals worth $941K as of Q2 2026.
Ameriprise bought 262,011 Rocket Pharmaceuticals shares in Q2 2026, an estimated $871K.
Rocket Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3431 holding.
Ameriprise first reported a position in Rocket Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
Ameriprise's Rocket Pharmaceuticals position peaked at $3.28M in Q2 2021.
180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.